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Introduction: Characterization of the type and topography of structural changes and their alterations throughout
the lifespan of individuals with autism is essential for understanding the mechanisms contributing to the autistic
phenotype. The aim of this stereological study of neurons in 16 brain structures of 14 autistic and 14 control
subjects from 4 to 64 years of age was to establish the course of neuronal nuclear and cytoplasmic volume
changes throughout the lifespan of individuals with autism.
Results: Our data indicate that a deficit of neuronal soma volume in children with autism is associated with deficits
in the volume of the neuronal nucleus and cytoplasm. The significant deficits of neuronal nuclear and cytoplasmic
volumes in 13 of 16 examined subcortical structures, archicortex, cerebellum, and brainstem in 4- to 8-year-old
autistic children suggest a global nature of brain developmental abnormalities, but with region-specific differences
in the severity of neuronal pathology. The observed increase in nuclear volumes in 8 of 16 structures in the autistic
teenagers/young adults and decrease in nuclear volumes in 14 of 16 regions in the age-matched control subjects
reveal opposite trajectories throughout the lifespan. The deficit in neuronal nuclear volumes, ranging from 7% to
42% in the 16 examined regions in children with autism, and in neuronal cytoplasmic volumes from 1% to 31%, as
well as the broader range of interindividual differences for the nuclear than the cytoplasmic volume deficits, suggest
a partial distinction between nuclear and cytoplasmic pathology.
Conclusions: The most severe deficit of both neuronal nucleus and cytoplasm volume in 4-to 8-year-old autistic
children appears to be a reflection of early developmental alterations that may have a major contribution to the
autistic phenotype. The broad range of functions of the affected structures implies that their developmental and
age-associated abnormalities contribute not only to the diagnostic features of autism but also to the broad
spectrum of clinical alterations associated with autism. Lack of clinical improvement in autistic teenagers and adults
indicates that the observed increase in neuron nucleus and cytoplasm volume close to control level does not
normalize brain function.
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For 70 years brain abnormalities in autism spectrum dis-
order (ASD) were viewed as static [1], and age-associated
alterations were beyond the scope of neuropathological
studies. However, more recent clinical and morphological
studies have disclosed evidence of developmental and age-
associated changes and have suggested a dynamic nature
of structural and functional changes throughout the life-
span of individuals with autism. The dichotomous concept
of autism distinguishes between the “early-onset” pattern
of clinical deficits, which emerge in the first year of life,
and regressive autism, which is diagnosed in children who
develop typically for the first year but lose acquired skills
and develop autistic symptoms in the second year of life
[2]. Development of the autistic phenotype typically takes
three years and consists of several steps, suggesting a
progressive involvement of brain structures and neuronal
networks. The earliest signs noted by approximately 50%
of parents are nonspecific and include behavioral changes
ranging from marked irritability to alarming passivity,
poor eye contact, and lack of response to parental voice or
interaction [3]. Behavioral modifications at the age of
12 months cross several functional domains including vis-
ual attention, imitation, social responses, motor control,
and reactivity [4]. Mild, atypical language deficits detected
at the age of 12 months typically become severe delays by
24 months [3,5]. At three years of age, all diagnostic fea-
tures, including difficulties in social reciprocity and com-
munication, and restricted/repetitive interests, are usually
present [6]. The improvement in daily living skills during
adolescence and in the early 20s and the plateau in skills
during the late 20s [7] indicate that the clinical phenotype
is formed during early childhood but undergoes further
modifications during adolescence and adulthood.
Early childhood brain overgrowth is widely cited as evi-
dence of age-associated developmental structural alte-
rations linked to clinical regression in autism. At birth, the
head circumference of neonates later diagnosed with aut-
ism is in the range of normal, but by 1 or 2 years of age, a
rapid increase is typically observed [8-10], which is
followed by growth inhibition resulting in only a 2% larger
brain size in autistic adults [11] or a smaller brain size in
comparison to control subjects [12]. The regression with
the loss of previously acquired skills, including verbal,
nonverbal, and social abilities, reported in 15% to 62% of
individuals with autism [13-17] suggests that clinical de-
terioration might be associated with structural changes.
The period of acceleration of head growth overlaps with
the onset of behavioral changes, whereas deceleration co-
incides with behavioral worsening in the second year of
life [18]; however, the cellular nature of accelerated brain
growth is unknown.
Among people with autism, one of the relatively com-
mon components of brain pathology is the presence ofdevelopmental abnormalities [19,20] contributing to
epilepsy. However, the probability of development of
epilepsy is a function of age [21], with a bimodal distri-
bution of the onset of seizures, one peak occurring be-
fore the age of 5 years, and the other after the age of 10
[22]. The highest prevalence is observed in patients
older than 12 years [23]. The frequency of epilepsy in
autism has been reported to range from 5% to 38.3%
[21], but long-duration video-electroencephalogram
(EEG) telemetry of children with ASD and the history of
regression reveal an epileptiform EEG in another 46% of
ASD cases [24]. The bimodal distribution of the onset
of seizures appears to be another marker of the age-
associated alterations that might be triggered by bio-
chemical and structural alterations [25].
The high prevalence of intellectual deficit and epi-
lepsy in ASD indicates that all three disorders share el-
ements of their pathophysiology [26], but that each of
these disorders has its own timing of onset and dy-
namic of clinical expression. Neuropathological studies
cannot monitor structural changes during the first
three years when the autistic phenotype is emerging
but before children have been diagnosed. However, the
significantly smaller volume of neuronal soma in 14 of
16 examined brain regions in 4- to 8-year-old children
with autism suggests that neuronal size alterations are
present earlier than 4 years of age and contribute to the
clinical phenotype [27]. The fact that only three regions
show a neuronal volume deficit in 11- to 23-year-old
autistic individuals indicates biochemical and structural
remodeling of the brain in teenagers and young adults.
One may assume that these alterations of neuronal
soma volume result from changes in the neuronal nu-
cleus or cytoplasm, or both. Nuclear size is only par-
tially regulated by chromatin organization [28], and
experimental studies indicate that alterations of cyto-
plasm components have a significant impact on nuclear
size and function [29]. The overall goal of this study
was to establish the course of volume changes of the
neuronal nucleus and soma cytoplasm throughout the
lifespan, assuming that an altered trajectory reflects
neuronal development and maturation defects. The
broad spectrum of clinical features of autism (impaired
communication and social skills, repetitive and stereo-
typic behaviors, intellectual deficits [30], epilepsy or
epileptogenic activity in the majority of autistic individ-
uals [25,26], and other clinical alterations) suggests mul-
tiregional rather than topographically limited brain
pathology. The aim of our study of neuronal nucleus and
cytoplasm volumes in 16 brain regions in autistic and con-
trol subjects was to characterize the global pattern of sub-
cellular changes that may correspond to a broad spectrum
of behavioral alterations in autism, including intellectual
deficits and epilepsy. To detect differences between the
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cytoplasm alterations throughout the lifespan 4- to 8-, 11-
to 23-, and 29- to 60-year-old autistic and control subjects
were examined.
Materials and methods
The brain hemispheres used in this project were pre-
served for several parallel studies designed to detect the
global pattern of developmental abnormalities of neuro-
genesis, migration, and dysplastic changes [19,31] and
to establish the global pattern of alterations of the number
and size of neurons in the cerebral cortex [27,32-35],
subcortical structures, cerebellum, and brainstem [27,35].
Provisionally, 39 brains were assigned to the stereological
study, including 21 brains from autistic individuals and 18
from controls. However 11 brain samples (seven autistic
and four controls) were excluded because postmortem
examination revealed pathology not related to autism,
changes associated with mechanisms of death, or post-
mortem autolysis, which may distort the results of ste-
reological estimates. Application of these criteria resulted
in inclusion of brains of 14 individuals diagnosed with aut-
ism, including 10 males and four females 4 to 60 years of
age, and 14 control subjects, including nine males and five
females 4 to 64 years of age.
Diagnosis of autism was confirmed with the Autism
Diagnostic Interview-Revised (ADI-R) [6]. The intellectual
disability of eight subjects (61%) ranging from mild to
severe was determined with the Wechsler Intelligence
Scale for Children III and the Woodcock-Johnson Tests
of Achievement-Revised. Seven of the 14 autistic subjects
(50%) were diagnosed with seizures, and in five cases,
death was seizure-related (36%). Neuropathological exam-
ination revealed focal developmental abnormalities of
neurogenesis, migration, and dysplastic changes in the
brains of 92% of autistic subjects [19].
The difference between the postmortem interval (PMI) in
the control group (6–28 hours; 16.7 hours on average;
standard deviation, SD ± 6.6 hours) and in the autistic
group (8–50 hours; 21.9 hours on average; ± 11.4 hours)
was insignificant. Also, the difference between the average
weight of the brains in the autistic group (1,453 g) and in
the control group (1,372 g) was insignificant. The brain
hemisphere was fixed with 10% buffered formalin for an
average of 408 days in the control group (range 52–
1,819 days) and 905 days (range 75–4,560 days) in the aut-
istic cohort. Neither the average time of brain hemisphere
dehydration in ethyl alcohol (36 days in the control group
and 38 days in the autistic group) nor the reduction of
brain hemisphere weight during dehydration (47% ± 7% in
the autistic and 45% ± 7% in the control group) were signifi-
cantly different. Brain hemispheres were embedded in 8%
celloidin [36] and cut into serial 200-μm-thick sections that
were stained with cresyl violet and mounted with Acrytol.Stereological analysis
To establish the global pattern of neuronal volume alter-
ations, the volume of the neuronal nucleus and cyto-
plasm was estimated in 16 brain structures/neuronal
populations, including the amygdala, entorhinal cortex,
Ammon’s horn, claustrum, caudate nucleus, putamen,
globus pallidus, nucleus accumbens, thalamus including
the magno- and parvocellular layers of the lateral gen-
iculate nucleus (LGN), substantia nigra, and magnocel-
lular basal complex (MBC); Purkinje cells and dentate
nucleus in the cerebellum; and the inferior olive in the
brainstem. Neurons were distinguished from glial cells by
using several morphological features including neuron
size, shape, and spatial orientation typical for specific
layers, sectors, and brain nuclei. Additional feature were
the pattern of staining and distribution of nuclear chroma-
tin, the distinct nucleolus in the majority of examined
neuronal populations, and cytoplasm morphology. Small
and round nuclei with uniform, intense staining of nuclear
chromatin distinguished oligodendrocytes from astrocytes,
which had large round nuclei with a small amount of dis-
persed chromatin and an undetectable nucleolus.
The volume of neuronal soma and nucleus was deter-
mined with the nucleator method [37] using Micro-
Brightfield software (Stereo Investigator, version 7.003,
MBF Bioscience, Williston, VT, USA). Five rays were
used to estimate the volume of the cell and the nucleus.
Five points of intersection of systematic randomly ro-
tated radii with the nuclear and cell border were marked.
The neuronal soma and cell nucleus volumes were esti-
mated from the lengths of radial cellular segments. The
volume of the cytoplasm was calculated as the difference
between neuronal body and nucleus volume. Measure-
ments were performed using a workstation consisting of
an Axiophot II (Carl Zeiss, Goettingen, Germany) light
microscope with Plan Apo objectives 1.25× (numerical
aperture, N.A., 0.15) or 2.5× (N.A. 0.075) (border lines
of region of interest), 40× (N.A. 0.75) or 63× (N.A. 0.9)
(neuronal and nuclear measurements); a specimen stage
with a three-axis, computer-controlled stepping motor
system (Ludl Electronics; Hawthorne, NY, USA); and a
CCD color video camera (CX9000 MBF Bioscience).
We used from four equidistant serial sections [38] in
structures with relatively uniform cytoarchitecture (caudate
nucleus, putamen, and globus pallidus) to 12 or 14 serial
sections in more heterogeneous structures such as the
amygdala or Ammon’s horn. An optical fractionator sys-
tematic random sampling scheme was applied using
Stereo Investigator (MBF Bioscience). The number of
virtual counting spaces was adjusted to region-specific
numerical density and ranged from 59, in small neuronal
groups in the MBC, to 664 for Purkinje cells with signifi-
cant variations in the numerical density per counting
space. To achieve a Schaeffer coefficient of error (CE) of
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in individual cases ranged from 153 in the MBC to 509 in
the Ammon’s horn. The volume of the nucleus and cyto-
plasm in the cytoarchitectural subdivisions of the amyg-
dala, entorhinal cortex, Ammon’s horn, and substantia
nigra are presented as a mean value for the entire struc-
ture. Details of the applied methods and anatomical
boundaries of the examined brain structures and their
cytoarchitectural subdivisions have been described in de-
tail in Wegiel et al. [27].
Statistical analysis
This study analyzed the effect that autism has on nu-
cleus and cytoplasm volume, with age-matched controls
as a comparison group. Data have been post-stratified to
adjust for the differing numbers of neurons sampled per
individual so as to weight each individual equally. Any
data points more than 1.5 times the interquartile range
below the 25th percentile or an equal amount above the
75th percentile for each structure or subdivision were
considered outliers and were omitted from analyses. The
removed data accounted for 0.3% of all records.
Analyses were carried out separately for three groups
of autistic cases: 4–8 years, 11–23 years, and 36–60
years of age. Three groups of controls were selected to
provide age-matching at the group level. The age ranges
for control groups were 4–8 years, 14–23 years, and 29–
64 years of age. Our previous study of neuronal soma
volume alterations throughout the lifespan revealed a
significant neuron soma volume deficit in 14 of 16 ex-
amined regions in children with autism 4 to 8 years of
age, but the number of regions with a significant deficit
of neuronal soma volume decreased to three in autistic
teenagers/young adults (11 to 23 years of age) and stabi-
lized at four in subjects 36 to 60 years of age. To main-
tain compatibility of results from the previous study and
this analysis of neuron nucleus and cytoplasm volume,
the same age divisions were applied.
Comparisons were carried out across 16 regions. Ad-
justment for multiple comparisons was performed using
the Benjamini-Hochberg method [39] to maintain a false
discovery rate (FDR) of 0.05. Accordingly, p values of
0.019 or less were considered statistically significant.
Analyses were conducted using versions 11.1 and 12.1 of
the Stata statistical package [40,41].
Following the procedure developed in our previous
analyses of the effects of potential confounders [27] in-
cluding PMI (in hours), fixation time (in days), brain
weight (in grams), brain weight loss during processing
and dehydration (as a percentage), duration of dehydra-
tion (in days), history of seizures, and sudden and unex-
plained death in patients with known epilepsy (SUDEP),
analyses were controlled for the log of the PMI, days of
dehydration, and weight loss during dehydration.The statistical significance of the differences in mean
neuronal volumes between autistic and control brains
and between pairs of age ranges was computed in gen-
eral linear mixed models adjusted for the autocorrelation
of measurements within each brain by using the xtmixed
procedure in version 12 of the Stata statistical package
[41]. This method takes into account the variance
among measurements of each individual while assessing
the significance of the differences between the brains of
autistic and control individuals.
Results
Brain region–specific proportions between neuronal
soma, nucleus, and cytoplasm volumes
In 16 examined brain regions in 4- to 8-year-old control
subjects, the mean volume of nuclei varied from 246 μm3
in small neurons in the putamen to 815 μm3 in the largest
neurons in the substantia nigra (Table 1). The percentage
of cell volume occupied by the nucleus was the smallest in
large neurons, such as Purkinje cells (5%), and the largest
in small neurons such as in the nucleus accumbens (24%)
(Figure 1).
Nuclear and cytoplasmic volume deficits in 4- to 8-year-
old autistic children
A significant, brain region–specific, developmental neur-
onal nucleus volume deficit was identified in 13 brain
structures in autistic subjects. The neuronal nucleus vol-
ume deficit ranged from −42% in the nucleus accumbens
and thalamus to −7% in the substantia nigra (Table 1;
Figure 1). A profound nucleus volume deficit (>40%)
was observed in the nucleus accumbens, thalamus, and
claustrum; very severe (>30%) in Purkinje cells; severe
(<30%) in the amygdala, putamen, entorhinal cortex, and
MBC; moderate (<20%) in the globus pallidus, parvocel-
lular lateral geniculate nucleus, Ammon’s horn, and in-
ferior olive; and mild (<10%) in the substantia nigra. In
three regions (dentate nucleus, caudate nucleus, and
magnocellular layer of the LGN), the difference between
the neuronal nucleus volume in autistic and in control
children was high, but the significance level was >0.019
when controlling for PMI, time of fixation and dehydra-
tion, and brain weight loss during dehydration.
The mean nucleus volume deficit was significantly more
prominent than the cytoplasmic volume deficit. The neur-
onal cytoplasm volume deficit ranged from −32% in the
nucleus accumbens to −4% in the substantia nigra
(Figure 1). Only in Purkinje cells was the nuclear and cyto-
plasmic volume deficit the same (−31%). The match be-
tween the neuronal and the nuclear volume was not
recorded in the version 7.001 of Stereo Investigator that
was used. For this reason, the volume of the cytoplasm was
calculated as the difference between the volume of the cell
body and of the cell nucleus for each structure/subject
Table 1 The difference between the mean volume of neuronal nucleus in three age groups of control and autistic
subjects
Brain structure 4- to 8-year-old subjects 11- to 23-year-old subjects 29- to 64-year-old subjects













Nucleus accumbens 281 ± 44 163 ± 49 -42% 0.001 226 ± 52 213 ± 54 0.959 ns 239 ± 34 253 ± 7 0.224 ns
Purkinje cells 575 ± 63 394 ± 77 -31% 0.001 561 ± 83 552 ± 168 0.635 ns 569 ± 63 654 ± 189 0.368 ns
Claustrum 395 ± 32 233 ± 371 -41% 0.001 360 ± 49 255 ± 67 -29% 0.001 267 ± 16 307 ± 76 0.841 ns
Thalamus 645 ± 56 371 ± 56 -42% 0.001 439 ± 95 433 ± 77 0.186 ns 462 ± 68 581 ± 103 0.035 ns
Globus pallidus 625 ± 93 503 ± 55 -19% 0.001 417 ± 103 479 ± 95 0.611 ns 478 ± 60 489 ± 75 0.918 ns
Dentate nucleus 510 ± 168 305 ± 152 0.104 ns 448 ± 20 489 ± 122 0.312 ns 397 ± 53 501 ± 128 + 26% 0.008
Entorhinal cortex 561 ± 67 408 ± 49 -27% 0.001 502 ± 110 444 ± 98 -11% 0.002 452 ± 69 484 ± 102 0.465 ns
Amygdala 606 ± 24 431 ± 74 -29% 0.001 595 ± 60 520 ± 88 0.691 ns 548 ± 48 498 ± 116 0.184 ns
Magnocellular basal complex 656 ± 45 476 ± 45 -27% 0.001 575 ± 46 581 ± 51 0.051 ns 558 ± 116 611 ± 131 0.028 ns
Putamen 246 ± 39 180 ± 32 -27% 0.014 244 ± 52 231 ± 51 0.443 ns 213 ± 27 223 ± 34 + 5% 0.004
Caudate nucleus 256 ± 54 181 ± 52 0.269 ns 229 ± 44 234 ± 49 0.284 ns 182 ± 26 234 ± 56 + 28% 0.001
Inferior olive 613 ± 122 507 ± 125 -17% 0.001 525 ± 67 553 ± 103 0.905 ns 508 ± 68 551 ± 73 0.481 ns
Magnocellular LGN 455 ± 66 382 ± 85 0.364 ns 457 ± 33 483 ± 85 + 5% 0.001 502 ± 20 567 ± 36 + 13% 0.002
Parvocellular LGN 268 ± 50 217 ± 47 -19% 0.005 264 ± 25 263 ± 48 0.145 ns 284 ± 28 335 ± 37 + 18% 0.001
Substantia nigra 815 ± 122 756 ± 50 -7% 0.001 811 ± 114 816 ± 97 0.202 ns 646 ± 56 685 ± 65 0.057 ns
Ammon’s horn 702 ± 40 576 ± 72 -18% 0.001 702 ± 72 631 ± 79 0.246 ns 683 ± 110 706 ± 138 + 3% 0.002
Significance levels computed controlling for post-mortem interval, days of fixation, days of dehydration, and weight loss during dehydration. Mean nucleus
volume ± SD; SD, standard deviation; ns, not significant; LGN, lateral geniculate nucleus.
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the volume of the neuronal cytoplasm could not be
determined.
The difference between courses of age-associated
changes in nucleus and cytoplasm volume in autistic and
control group
To detect age-associated changes in neuronal nucleus
volume throughout the lifespan of autistic subjects, the
volume of nuclei in 16 brain regions in 4- to 8-, 11- to
23-, and 29- to 40-year-old autistic subjects was compared
with that of age-matched control subjects (Table 1).
Whereas in 4- to 8-year-old autistic children, the nu-
clear volume deficit was significant in 13 of 16 regions,
the number of regions with significant deficits was re-
duced to only two in 11- to 23-year-old autistic individ-
uals (Table 1, Figure 2), and there was no nuclear
volume deficit in 29- to 60-year-old autistic subjects.
The increase in neuronal nucleus volume with age in
autistic subjects is reflected in the nuclei that were lar-
ger than control nuclei in the magnocellular layer of the
LGN in 11- to 23-year-old autistic subjects, and the sig-
nificantly larger neuronal nuclei in six of 16 regions in aut-
istic adults 29– 60 years of age, including the Ammon’s
horn, dentate nucleus, magnocellular and parvocellular
layers of the LGN, caudate nucleus, and putamen. The
increase in the seven other regions did not reachsignificance. These data indicate that the number of re-
gions with a non-significant difference between the
neuronal nucleus volume in autistic and control sub-
jects increased from three in children, to 13 in teen-
agers/young adults, and ten in older adults.
Comparative analysis of the volume of neuronal
nucleus frequency distribution in 4- to 8-year-old and
11- to 64-year-old autistic subjects versus age-matched
control subjects demonstrates a high percentage of small
neuronal nuclei in autistic children. However, in most of
the examined regions, the difference between neuronal
nucleus volume in adult autistic and in control subjects
is significantly reduced or undetectable (Figure 3). These
data suggest an increase of neuron nucleus volume in
the autistic group and a decrease in the control group.
Trajectories of neuronal nucleus volume modifications
during the lifespan in autistic and control cohorts
examined independently
To define the differences between the trajectories of age-
associated alterations in neuronal nucleus volume in aut-
ism and control subjects, the volume of nuclei has been
compared in three age groups within the autistic cohort
and within the control cohort. The study revealed opposite
trends in autistic and control cohorts (Table 3, Figure 4).
The dominant feature of the autistic cohort was the signi-
ficant increase in the neuronal nucleus volume in eight
Figure 1 Region-specific proportion between nucleus and neuron soma volume and the range of neuronal nucleus and cytoplasm
volume deficit in children diagnosed with autism. Percent of cell volume occupied by nucleus in 4- to 8-year-old control subjects illustrates
neuron type– or region-specific proportions between cell and nucleus volume, with the smallest contribution of nucleus to neuron volume in the
largest neurons (Purkinje cell, 5%), and the largest contribution in the smallest neurons (nucleus accumbens, 24%). Neuronal nucleus volume deficits
(control 100%) in 4- to 8-year old autistic subjects range from mild (<10%) in the substantia nigra to profound (>40%) in the n. accumbens, thalamus,
and claustrum. The cytoplasm volume deficit is less prominent and ranges from 4% in the substantia nigra to 32% in the nucleus accumbens. PC,
Purkinje cell; SN, substantia nigra; MBC, magnocellular basal complex; DN, dentate nucleus; GP, globus pallidus; LGNm, magnocellular layer of the lateral
geniculate nucleus; IO, inferior olive; Th, thalamus; AH, Ammon’s horn; Am, amygdala; LGNp, parvocellular layer of the lateral geniculate nucleus; EC,
entorhinal cortex; Cl, Claustrum; Pu, putamen; CN, caudate nucleus; Ac, nucleus accumbens.
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thalamus, magno- and parvocellular layers of the LGN,
inferior olive, entorhinal cortex, dentate nucleus, and
claustrum. The increase observed in six other regions
(substantia nigra, Ammon’s horn, amygdala, nucleus,
accumbens, caudate nucleus, and putamen) and Purkinje
cells in cerebellum did not reach significance. A small but
significant decrease of neuronal nucleus volume was
found only in the globus pallidus.
The characteristic feature of the control cohort was the
decrease in neuronal nucleus volume in one of the two
older groups in eight regions and in both older age groupsin the six other regions, including the thalamus, globus
pallidus, claustrum, nucleus accumbens, caudate nucleus,
and putamen. Only two regions (magno- and parvocellular
layers of the LGN) did not reveal significant age-
associated modifications of the neuronal nucleus volume
in control cohorts. In spite of the general shift towards
larger nuclei in autistic subjects and towards smaller nu-
clei in the control group, there are significant inter-
regional differences in neuronal volume growth or reduc-
tion during the lifespan in autistic and control cohorts.
To explain why very striking differences in the mean
volume of neuronal nuclei in the nucleus accumbens of
Table 2 The difference between the mean volume of neuronal cytoplasm in autistic and control cohorts
Brain structure 4- to 8-year-old subjects 11- to 23-year-old subjects 29- to 64-year-old subjects













Nucleus accumbens 900 ± 108 615 ± 122 -32% 864 ± 113 808 ± 46 -6% 758 ± 113 849 ± 242 + 12%
Purkinje cells 11,060 ± 466 7,653 ± 2,176 -31% 10,899 ± 1,261 9,222 ± 358 -15% 10,275 ± 1,434 7,735 ± 860 -25%
Claustrum 1,599 ± 167 1,173 ± 230 -27% 1,589 ± 75 1,358 ± 129 -15% 1,518 ± 180 1,415 ± 124 -7%
Thalamus 3,057 ± 220 2,311 ± 225 -24% 2,696 ± 255 2,617 ± 283 -3% 2,768 ± 214 2,954 ± 218 + 7%
Globus pallidus 5,011 ± 190 3,999 ± 336 -20% 4,061 ± 864 3,875 ± 660 -5% 4,523 ± 935 4,441 ± 1,008 -2%
Dentate nucleus 7,734 ± 974 5,913 ± 1,168 -23% 7,883 ± 751 6,617 ± 951 -16% 7,335 ± 516 6,505 ± 2,047 -11%
Entorhinal cortex 1,862 ± 167 1,434 ± 178 -23% 1,948 ± 135 1,597 ± 186 -18% 1,969 ± 102 1,980 ± 432 + 1%
Amygdala 2,427 ± 125 1,878 ± 287 -23% 2,386 ± 56 2,153 ± 282 -10% 2,398 ± 256 2,054 ± 413 -14%
Magnocellular basal complex 7,728 + 475 6,076 ± 302 -21% 7,639 ± 750 7,489 ± 556 -2% 7,867 ± 1,087 7,563 ± 1,028 -4%
Putamen 1,071 ± 105 914 ± 92 -15% 820 ± 163 758 ± 125 -8% 679 ± 98 770 ± 165 + 13%
Caudate nucleus 943 ± 106 754 ± 93 -20% 988 ± 148 958 ± 103 -3% 874 ± 160 983 ± 165 + 12%
Inferior olive 3,852 ± 1,428 3,325 ± 352 -14% 3,136 ± 677 3,619 ± 575 + 15% 3,409 ± 616 3,668 ± 72 + 8%
Magnocellular LGN 4,786 ± 266 4,261 ± 665 -11% 5,010 ± 87 4,855 ± 695 -3% 5,119 ± 655 5,230 ± 473 + 2%
Parvocellular LGN 2,337 ± 280 2,249 ± 316 -4% 2,563 ± 156 2,260 ± 378 -12% 2,547 ± 356 2,614 ± 445 + 3%
Substantia nigra 8,193 ± 1,344 7,847 ± 615 -4% 8,147 ± 487 8,271 ± 730 + 1% 8,679 ± 2,270 10,416 ± 1,146 + 20%
Ammon’s horn 2,712 ± 152 2,444 + 494 -10% 2,972 ± 221 2,515 ± 297 -3% 2,892 ± 452 2,752 ± 718 -5%
Mean cytoplasm volume ± SD; LGN, lateral geniculate nucleus.
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spectively), Purkinje cells (40% and 66%, respectively),
dentate nucleus (60%), amygdala (21%), putamen (28%
and 24%, respectively), caudate nucleus (29% and 29%,
respectively), magnocellular LGN (26%), and parvocellu-
lar LGN (21%) are not statistically significant, individual
case estimates were analyzed. Comparison of the neur-
onal nucleus volume in four autistic children 4–8 years
of age revealed prominent inter-individual differences in
the mean nucleus volume as well as broad variations in
the nucleus size within case.
The box plot shown in Figure 5 illustrates neuronal nu-
cleus volume distributions in the six brain structures with
the most severe volume deficit and demonstrates that in all
these structures, the median neuronal nucleus volumes for
all four autistic children were below the range of those for
the four 4- to 8-year-old control children. In the majority of
autistic subjects 36–60 years of age, the neuronal nucleus
volume is increased to the range of that in the control
group. The box plot demonstrates an opposite pattern of
changes in the 29- to 64-year-old control group, with a re-
duction in the median neuronal nucleus volume in com-
parison to that in the 4- to 8-year-old control children. The
increase in the volume of the neuronal soma cytoplasm in
36- to 60-year-old autistic subjects in comparison to that in
autistic children as well as the partial decrease in that vol-
ume in adult controls in comparison to in control children
replicates the pattern of nuclei alterations in both cohorts.Discussion
Global pattern of abnormal neuron growth in autism
Morphometric studies designed to detect clinicopatho-
logical correlations demonstrated links between func-
tional deficits observed in autism, and reduced size of
neurons in several cortical regions including superior
and middle frontal gyrus [42], inferior frontal cortex (BA
44 and 45) [32], fusiform gyrus [34], anterior midcingu-
late [43] and anterior cingulate cortex [44], as well as
Purkinje cells in the cerebellum [45], and neurons in the
brainstem superior olive [46]. In addition, neuropatho-
logical studies not supported with morphometric methods
revealed small neurons in the amygdala, entorhinal cortex,
mammilary body, [47], Ammon’s horn [48], medial septal
nucleus [49], cerebellar nuclei and inferior olive [50]. The
present study of neuronal nucleus and cytoplasm volumes
and our previous study of cell soma volume in 14 brain re-
gions [27], combined with parallel studies of several cor-
tical regions in the same cohort, and neuropathological
studies listed in Table 4, disclose the global nature of de-
velopmental alterations with multiregional developmental
alterations rather than changes limited to a few regions.
The detected pattern of developmental alterations of neur-
onal growth may contribute to the diagnostic features of
ASD, as well as a number of associated conditions, includ-
ing intellectual deficits, depression, obsessive-compulsive
disorders, anxiety, oppositional/defiant disorder, aggres-
sion, and self-injurious behaviors [51,52]. The absence of
Figure 2 Alterations of the neuronal nucleus volume deficit throughout the lifespan of subjects diagnosed with autism. Comparison of
neuronal nucleus volume (μm3) in 4- to 8-year-old autistic and control subjects revealed significant nucleus volume deficits (blue arrows) in 13 of
16 brain regions examined. In 11- to 23-year-old autistic subjects, the deficit was significant in only two of 16 structures. In 29- to 64-year-old
autistic subjects, differences in neuronal nucleus volume were not significant in 10 structures, whereas the volume of nuclei of autistic subjects
significantly exceeded the volume of nuclei of control subjects in six other structures (white arrows).
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with little-known relevance to autism, such as postero-
inferior occipitotemporal gyrus [53], primary visual cortex
[34] and prefrontal cortex [54] support the specificity of
neuropathological changes in autism. The broad spectrum
of deficits of neuronal soma, nucleus, and cytoplasm
volume shown in this study reveals brain region/neuron
type-specific sub-patterns of developmental abnormal-
ities in autism.Patterns of age-associated nucleus and cytoplasm changes
throughout the lifespan in autistic and control groups
The present study demonstrates that alterations of neur-
onal soma volume in autism are associated with alter-
ations of the nucleus and cytoplasm volumes, and that the
volumes of these two neuronal body compartments is the
lowest in 4- to 8-year-old autistic children. The detected
brain region- and neuron type-specific neuronal volume
deficit suggests that this developmental abnormality is
Figure 3 Multiregional prevalence of small neuronal nuclei in 4- to 8-year-old children with autism. Frequency distribution of neuronal
nucleus volume in six selected structures demonstrates a significant shift towards small neuronal nuclei in 4- to 8-year-old autistic children (continuous
line) in comparison to age-matched control subjects (dotted line), but differences between 11- to 64-year-old autistic and control subjects are
significantly reduced or are undetectable.
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made at the age of 3 years or older, verification of this hy-
pothesis on the basis of current diagnostic criteria is im-
possible. However, a study of neuronal progenitor cells
suggests that in autism, neuronal size might be defined at
age much less than 3 years. The exposure of human
neuronal progenitor cells originating from the fetal
cerebral cortex to media enriched with serum from autis-
tic donors ~3 years of age or from age-matched healthydonors revealed that in colonies that developed in “autis-
tic” conditions, the percentage of smaller cells was signifi-
cantly higher than in colonies exposed to sera of healthy
donors [55].
Whereas nuclear volume deficit was significant in 13
of 16 regions in 4- to 8-year-old autistic children, the
number of regions with a significant deficit was reduced
to only two in 11- to 23-year-old autistic individuals,
and there was no nuclear volume deficit in 29- to 60-
Table 3 Trajectory of neuronal nucleus volume changes throughout the lifespan of autistic and control subjects
Brain region Autism Control








4–8 y 11–23 y 36–60 y A/B A/C 4–8 y 14–23 y 29–64 y A/B A/C
Nucleus accumbens 163 213 253 31% 0.911 55% 0.904 281 226 239 −20% 0.001 −15% 0.001
Purkinje cells 394 552 654 40% 0.226 66% 0.468 575 561 569 −2% 0.000 −1 0.402
Claustrum 233 255 307 9% 0.081 32% 0.000 395 360 267 −9% 0.001 −32 0.000
Thalamus 371 433 581 17% 0.533 57% 0.000 645 439 462 −32% 0.000 −28% 0.000
Globus pallidus 503 479 489 −5% 0.357 −3% 0.000 625 417 478 −33% 0.001 −24% 0.000
Dentate nucleus 305 489 501 60% 0.257 64% 0.000 510 448 397 −12% 0.269 −22% 0.008
Entorhinal cortex 408 444 484 9% 0.857 19% 0.007 561 502 452 −10% 0.632 −19.6% 0.000
Amygdala 431 520 498 21% 0.140 16% 0.732 606 595 548 −2% 0.001 −10% 0.026
Magnocellular basal complex 476 581 611 22% 0.000 28% 0.030 656 575 558 −12% 0.000 −15% 0.064
Putamen 180 231 223 28% 0.332 24% 0.830 246 244 213 −1% 0.019 −13% 0.007
Caudate nucleus 181 234 234 29% 0.374 29% 0.812 256 229 182 −11% 0.003 −29% 0.000
Inferior olive 507 553 551 9% 0.089 9% 0.000 613 525 508 −14% 0.000 −17% 0.150
Magnocellular LGN 382 483 567 26% 0.405 48% 0.002 455 457 502 0 0.255 10% 0.189
Parvocellular LGN 217 263 335 21% 0.578 54% 0.000 268 264 284 −1% 0.503 6% 0.436
Substantia nigra 756 816 685 8% 0.911 −9% 0.035 815 811 646 0% 0.367 −21% 0.002
Ammon’s horn 576 631 706 9% 0.509 23% 0.888 702 702 683 0% 0.316 −3% 0.000
Significance levels computed controlling for post-mortem interval, days of fixation, days of dehydration, and weight loss. Results were non-significant using a false
discovery rate (FDR) of p < 0.05. A/B and A/C not bootstrapped p-value.
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autistic subjects, deceleration of neuronal nuclear and
cytoplasmic growth during childhood is followed by ac-
celeration of neuronal volume growth during adolescence
and early adulthood. The detected pattern explains the dif-
ferences between characteristics of neuronal size in other
reports. In our cohort, the significant difference in volume
of neuronal soma (−24%) or nucleus in the amygdala
(−29%; p < 0.001) was detected only in the youngest autis-
tic subjects (4–8 years of age), and the difference in nu-
cleus and cell volume was not significant in older groups
(11–64 years of age). This result is similar to the result of
averaging of the neuronal size in the amygdala of 10- to
44-year-old autistic subjects [56], when the difference is
masked by an increase in the neuronal volume in autistic
subjects and a decrease in the neuronal volume in control
subjects.
Common mechanisms contributing to smaller neuron size
in neurodevelopmental disorders
Autism and Rett syndrome overlap phenotypically and
neuropathologically. In both conditions, a similar de-
layed regression after apparently normal prenatal and
early postnatal development is observed [57]. Rett syn-
drome is caused by over 300 mutations of the methyl-
CpG-binding protein 2 (MECP2) gene [58,59]. The
MECP2 gene encodes methyl CpG–binding protein-1
(MeCP2), a transcriptional repressor required for properdevelopment of post-migratory neurons, but with cell-
specific differences in MeCP2 levels [60]. In Rett
syndrome, normal head circumference at birth, but de-
celeration of growth at 2–3 months of age results in a
12–34% deficit in brain weight and volume [61,62], re-
duced neuronal size in the cortex, thalamus, basal gan-
glia, amygdala, and hippocampus [63], decrease in the
size of cortical minicolumns [64], and reduced dendritic
branching [65]. Furthermore, the reduced size of pyram-
idal neurons and the lesser complexity of dendritic ar-
borizations in MeCP2 mutant mice indicate that MeCP
2 is involved in maturation and the maintenance of neu-
rons, including dendritic integrity and synaptogenesis
[66,67]. The significant reduction in MeCP2 expression
in 79% of autism, 100% of Angelman syndrome, 75% of
Prader-Willi syndrome, and 60% of Down syndrome
cases [57] compared to age-matched controls sug-
gests that altered MeCP2 expression contributes to
abnormal postnatal brain development and to an
abnormal course of neuron maturation in neurodeve-
lopmental disorders [68].
MeCP2 is an abundant nuclear protein with elevated
expression during postnatal brain development [60]. The
chromatin-binding function of MeCP2 is required for
neuronal nucleus and nucleolus development and mat-
uration. Critical for this binding activity is an intact
methyl-binding domain at the amino terminus of the
MeCP2 protein [69]. During neuronal maturation, the
Figure 4 Increase of neuronal nuclei volume in teenagers and adults with autism, and decrease in control cohort. Estimates of nucleus
volume (μm3) in three age groups of subjects with autism revealed significant increase in eight brain regions (white arrows). In the control
cohort, the volume of neurons decreased significantly in 14 regions. The significance level was computed by controlling for post-mortem interval,
days of fixation, days of dehydration, and brain weight loss during dehydration. Large arrows indicate a significant difference in both age groups;
small arrow marks a significant difference in one of two age groups.
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matic nucleus with many randomly located chromocen-
ters and several nucleoli to a large, mostly euchromatic
nucleus with fewer and larger chromocenters and a
large, centrally located nucleolus [70]. In the absence of
MeCP2, the neuronal nuclei fail to increase in size at
normal rates during cell differentiation. Neurons lacking
MeCP2 have a significantly reduced rate of RNA synthe-
sis; however, re-expressing MeCP2 in mutant neurons
rescues the nuclear size phenotype in vitro [71] and in
Mecp2 mice [72]. Reduced expression of MeCP2 in the
majority of autistic subjects [57] appears to contribute to
nucleus volume deficit.
Alterations that may contribute to neuronal cytoplasm
volume changes throughout the lifespan of autistic
individuals
One may hypothesize that the increase in neuronal
soma, nucleus, and cytoplasm volume in autistic adoles-
cents corresponds to delayed cell development/matur-
ation. However, this assumption appears to be in conflict
with biochemistry- and immunocytochemistry-supportedneuropathological studies that demonstrate a broad
spectrum of pathology in the neuronal energy-generating
system, metabolism, degradation and storage systems, and
oxidative stress. These alterations affect major cytoplasmic
compartments, including mitochondria, endocytic vesi-
cles, lysosomes, and autophagic vacuoles, as well as
lipofuscin deposits and suggest that they may directly
contribute to the abnormal increase in cytoplasm vol-
ume in adolescence/adulthood.
Mitochondria are one of the major compartments of
neuronal cytoplasm. Mitochondrial DNA mutations and
copy number variations [73-75] support the hypothesis
of a mitochondrial pathology in ASD. Developmental al-
terations include the perturbations of mitochondrial en-
ergy generation that have been demonstrated in some
individuals diagnosed with ASD [76-80], and mitochon-
drial respiratory chain dysfunction [75].
Mitochondrial electron transport chain (ETC) complexes
generate the proton gradient used by ATP synthase to
catalyze ATP formation [81,82]. In autistic subjects, alter-
ations of ETC reveal brain region–specific differences, with
a decrease in the ETC protein levels in the cerebellum and
Figure 5 Difference between neuronal nucleus and cytoplasm volume distribution in control and autism group. Box plot illustrates
neuronal nucleus volume distributions in the six brain structures with the most severe volume deficit. The upper and lower boundaries of each
box represent the 75th and 25th percentiles of nucleus volume (μm3), respectively. The depth of the box represents the interquartile range (IQR).
The whisker above the box marks the maximum value unless any data point lies more than 1.5 times of the IQR above the 75th percentile. The
points outside it (outliers) are indicated by circles. The lower whisker and outliers are shown analogously. In all six brain structures, the median
volumes of neuronal nuclei in autistic children were below the range of the median volumes of four 4- to 8-year-old control children. The dominant
feature in 10 autistic subjects 36–60 years of age was an increase in the volume of nuclei in comparison to in autistic children, as shown as the IQR of
older subjects above the median value of children. The level of 75th percentile and the whisker above the box indicate that in the older cohort, the
volume of nuclei of the majority of subjects increases with age. The persistence of the volume of neuronal nuclei in the amygdala in a minority of
adults at the level of that of 4- to 8-year-old children suggests heterogeneity within the autistic group and indicates a lack of neuronal nucleus increase
in some autistic adults. The opposite pattern is observed in the 29- to 64-year-old control group, reflected in reduction of median neuronal nucleus
volume and IQR shift below the median value of control 4- to 8-year-old children. In general, the volume of cytoplasm increases with age in adult
autistic subjects and decreases in the control group.
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parietal cortices. Chauhan et al. [80] reported a significant
reduction in respiratory chain protein expression, with
lower levels of complexes II, III, and IV in the temporal
cortex of autistic children. ETC alterations are associated
with age. Children with autism 4–10 years of age have
lower levels of ETC proteins than control subjects; however,the difference in subjects from 14–39 years of age was not
significant [75,80]. Decreased complexes III and IV were
also reported by Tang et al. [83].
Cytoplasm volume changes might be directly related
to increased mitochondrial mass, as measured by levels
of the mitochondrial membrane proteins porin, Tom20,
and Tim23, and significant changes in the expression of
Table 4 Neuronal soma, nucleus and cytoplasm volume deficit in 4- to 8-year old autistic subjects compared to results
of previous qualitative and morphometric studies
Brain structure or neuron type Volume deficit in 4- to 8-year-old
autistic subjects
Alterations of neuron soma size detected in previous
studies
Nucleus Cytoplasm Soma
N. accumbens −42%* −32% −34%*
Thalamus −42%* −24% −27%*
Claustrum −41%* −27% −29%*
Purkinje cells −31%* −31% −31%* 24% Purkinje cell area deficit [45]
Amygdala −29%* −23% −24%* Reduced neuron soma size in some amygdala nuclei [47]
Magnocellular basal complex −27%* −21% −22%*
Putamen −27%* −15% −17% ns
Entorhinal cortex −27%* −23% −24%* Reduced neuron soma size [47]
Globus pallidus −19%* −20% −20%*
Parvocellular LGN −19%* −4% −5%*
Ammon’s horn −18%* −10% −12%* 27% neuron volume deficit in CA4 of 9 y old [48]
Inferior olive −17%* −14% −14% ns Enlarged neurons in less than 12 years old and smaller in
over the age of 22 years [50]
Substantia nigra −7%* −4% −5%*
Magnocellular LGN −16% ns −11% −12%*
Caudate nucleus −29% ns −20% −22%*
Dentate nucleus −40% ns −23% −25%* Enlarged neurons in less than 12 years old and smaller in
over the age of 22 years [50]
Superior olive * Significant neuron volume deficit in medial superior olive [46]
Superior and middle frontal gyrus *Significantly smaller neurons in six autistic subjects 4 to 24 years of age [42]
Inferior frontal cortex (BA 44 and 45) *Significant neuron volume deficit by 18% in layer III and V, and by 22% in layer VI [32]
Fusiform gyrus *Significant neuron volume deficit by 21% in layer V and by 13.4% in layer VI [34]
Anterior midcingulate cortex *Significant pyramidal neurons volume deficit in young children [43]
Posteroinferior occipitotemporal gyrus *No significant difference in pyramidal neurons volume [53]
Prefrontal cortex *Unchanged size of neurons [54]
Anterior cingulate cortex Significant neuron volume deficit in layers I-III and V-VI [44]
Mammillary body Smaller neurons [47]
Medial septal nucleus Smaller neurons [49]
Fastigial, globose, emboliform nucleus Enlarged neurons in less than 12 years old and smaller in over the age of 22 years [50]
The 16 regions marked with bold were examined in this study. The superior olivary complex and six neocortical regions marked with bold (*) were examined by
other researchers using significant amount of material from this cohort of 14 autistic and 14 control subjects. The significance of difference of the cytoplasm
volume was not determined due to software limitations.
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imbalance between mitochondrial biogenesis and
degradation in neurons in the temporal cortex of young
ASD subjects [83]. These alterations can change the
morphology, number, and function of mitochondria
[84]. Autophagosomes degrade damaged mitochondria,
producing excessive reactive oxygen species via ubiquitin-
mediated recognition and selective targeting [85]. Several
ubiquitin genes have been implicated in ASD [86], includ-
ing PARK2 that encodes parkin, which assists in mito-
chondria dystruction [87]. However, an increase in
compromised mitochondria suggests impaired mitophagy
in ASD [83].Reported mitochondrial alterations reflect the dis-
turbed energy production that coexists with alterations
of neuronal metabolism [75,88-90] and the enhanced
degradation of DNA, RNA, and proteins by oxidative
stress [80,91,92] that may result in enhanced cell organelle
turnover [77], excessive accumulation of products of deg-
radation [93], and pathological increase of the cytoplasm
and cell volume.
Enhanced anabolic APP processing in autism
Alternative cleavage of amyloid-β precursor protein (APP)
with α secretase releases non-amyloidogenic secreted
APPα (sAPPα) [94]. Recent studies revealed enhanced
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tases in such developmental disorders as autism and
fragile X syndrome (FXS) [88,95-98]. Sokol et al. [95]
and Ray et al. [89] reported two or more times higher
levels of total sAPP, including sAPPα, and a decrease in
the levels of both Aβ40 and Aβ42 in young children
with severe autism in comparison to children without
autism. A study of 25 autistic subjects revealed elevated
plasma sAPPα in 60% of children with autism (n = 25)
compared to healthy controls [98]. The elevated levels
of sAPPα in autistic individuals with severe autism but
not in neurotypical and mildly autistic subjects suggest
a link between levels of sAPPα and autism severity [89].
Neurons in the brain of control children and adults ac-
cumulate cell type–specific amounts of Aβ17–40/42, which
is the product of nonamyloidogenic APP processing with
α- and γ-secretase [99]. The enhanced cytoplasmic accu-
mulation of mainly N-terminally truncated Aβ was detected
in 11 of 12 examined brain regions in autistic children,
adolescents, and adults diagnosed with Dup15q11.2-q.13
(dup15) and in 8 of 12 regions in children, adolescents,
and adults with idiopathic autism, including neurons in all
three cortical regions, the amygdala, thalamus, Purkinje
cells, lateral geniculate nucleus, and dentate nucleus [100].
Enhanced non-amyloidogenic APP metabolism is associ-
ated with excessive accumulation of Aβ17–40/42 within the
organelles involved in proteolysis and storage of metabolic
remnants [92-100]. One may hypothesize that the ob-
served neuron type- and region-specific increase in the
volume of neuronal cytoplasm is a reflection at least in
part of a neuron type- and region-specific increase in
sAPPα production and neuron type- and region-specific
enhanced accumulation of Aβ17–40/42 in several cytoplas-
mic compartments, including endocytic vesicles, autopha-
gic vacuoles, lysosomes, and lipofuscin, and in minute
amounts in mitochondria. Application of Lamp 1 as a
lysosomal marker revealed that approximately 20–30% of
neuron cytoplasmic Aβ17–40/42 is detected in the en-
dolysosomal pathway, whereas another 20–30% of
neuronal Aβ17–40/42 is accumulated in the lipofuscin
[92,100]. An increase in the percentage of Aβ17–40/42-
accumulating neurons appears to be associated with an
increase in the number of lipofuscin-containing neu-
rons observed in our study [100] and in an increase in
the number of lipofuscin-containing neurons by 69% in
Brodmann area 22, by 149% in area 39, and by 45% in area
44 [93]. The higher prevalence of excessive Aβ17–40/42 in
autistic subjects with dup(15), the early onset of intract-
able seizures, and the high risk of SUDEP support re-
ports demonstrating a link between enhanced sAPPα
levels and severe autism [88,89,95,98]. The appearance
of diffuse plaques in three autistic subjects 39–53 years
of age suggests an age-associated risk of alterations
of APP processing with enhanced short-form Aβdeposition in the cytoplasm and full length of Aβ in
nonfibrillar plaques [101].
Biochemical reports demonstrate an increase in the
level of marker of lipid peroxidation (malondialdehyde,
MDA) in the plasma of autistic children [102] and in the
cerebral cortex and cerebellum [103]. Lipid peroxidation
products were detected in all mitochondria and lipofus-
cin deposits, numerous autophagic vacuoles, and lyso-
somes. Neuronal Aβ was colocalized with markers of
oxidative stress, including 4-hydroxy-2-nonenal (HNA)
and MDA, and increased levels of Aβ levels correlated
with higher levels of HNE and MDA [92].
It appears that a neuron type- and region-specific
pattern of these metabolic changes and oxidative stress
contribute to the cytoplasmic organelle damage, deg-
radation and storage of products of degradation in
growing lipofuscin deposits, and the cell cytoplasm al-
terations detected in this study. The prevalence of this
pathology in children/young autistic subjects but with
no evidence of significant neuronal loss suggests that
oxidative damage of cytoplasmic organelles is associ-
ated with an increased turnover/repair of affected cell
components. In addition, some reports suggest that in-
creased processing of APP may contribute to autistic
functional alterations [89,95].
Conclusions
This first study of the volume of neuronal nucleus and
cytoplasm in autistic subjects reveals a brain region–
and neuron type–specific deficit in the volume of both
cell compartments in affected 4-to 8-year-old children
compared to control subjects. The most severe volume
deficit in the youngest group suggests that these devel-
opmental abnormalities contribute to emergence of the
autistic phenotype before the age of three years. Signifi-
cant pathology in 13 of 16 examined regions reflects the
global nature of developmental deficits and their potential
contribution to a broad spectrum of clinical autism mani-
festations. The observed pattern of nuclear and cytoplas-
mic alterations suggests four neuron type- and brain
region-specific phases of changes in neuron morphology:
(a) abnormal as well as delayed neuronal nucleus and
cytoplasmic growth before the third year of life, (b) severe
volume deficit in early childhood (4–8 years) reflecting
developmental abnormalities in first three years of life,
(c) significant increase in neuronal nucleus and cytoplas-
mic volume during adolescence, and (d) relatively modest
further modifications during adulthood. The increase in
nuclear and cytoplasmic volumes close to the control level
in the majority of examined regions in teenagers and
adults appears to reflect alterations in neuronal energy
production, metabolism, and oxidative stress, rather than
delayed neuron growth with an adjustment of structure
and function.
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